Amgen 2010 Annual Report Download - page 54

Download and view the complete annual report

Please find page 54 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

AMG 785
AMG 785 is a humanized monoclonal antibody that targets sclerostin, a protein secreted by bone cells that
inhibits bone formation. AMG 785 (also known as CDP7851) is being developed in collaboration with UCB for
bone-related conditions, including PMO and fracture healing.
In 2009, we initiated phase 2 studies of AMG 785 for the treatment of PMO and fracture healing (tibial
diaphyseal).
In 2010, we initiated a phase 2 study of AMG 785 for the treatment of fracture healing (hip).
AMG 827
AMG 827 is a fully human monoclonal antibody that binds to and blocks signaling via the interleukin-17
receptor. It is being investigated as a treatment for a variety of inflammatory disorders.
In 2009, we initiated phase 2 studies of AMG 827 as a potential treatment for psoriasis and RA. In 2010, we
initiated phase 2 studies of AMG 827 as a potential treatment for Crohn’s disease and asthma. We received the
results from the phase 2 study in psoriasis in 2010 and plan to share these data at an upcoming medical meeting.
AMG 853
AMG 853 is an orally-administered small molecule antagonist of the CRTH2 and D-prostanoid receptors of
prostaglandin D2. It is being investigated as a treatment for asthma.
Phase 1 single- and multiple-ascending dose studies have been completed. A global, randomized, double-
blind, placebo controlled, multiple dose phase 2 study in subjects with inadequately controlled asthma was initiated
in December 2009 and is ongoing.
Conatumumab
Conatumumab is a fully human monoclonal antibody agonist that targets death receptor 5 and induces
apoptosis in sensitive tumor cells. It is being investigated as a cancer treatment.
We have an ongoing phase 2 study in mCRC.
Nplate»(romiplostim)
Nplate»is a peptibody agonist of the TPO receptor.
In December 2010, we announced results at a medical meeting from studies evaluating Nplate»in adult and
pediatric patients with chronic immune (idiopathic) thrombocytopenic purpura.
Results from completed phase 2 studies in myelodysplastic syndromes (“MDS”) were presented in 2010. In
late February 2011, an independent Data Monitoring Committee (“DMC”) recommended that we modify the study
conduct in another ongoing phase 2 study exploring the use of Nplate»in MDS, expressing concern that the
demonstrated benefits seen in treated patients might not outweigh the potential risks of accelerated disease
progression to AML. The DMC was also concerned that transient blast cell increases in the Nplate»arm put patients
at risk for diagnosis of, and treatment for, AML, irrespective of whether or not the disease had actually developed.
We accepted the recommendation of the DMC and notified investigators that subjects in this study should
discontinue Nplate»treatment and enter into the observational long-term follow-up phase of the study.
Nplate»is also being evaluated in chemotherapy-induced thrombocytopenia.
Omecamtiv mecarbil (AMG 423)
Omecamtiv mecarbil is a small molecule activator of cardiac myosin. Omecamtiv mecarbil is being inves-
tigated to improve cardiac contractility in subjects with heart failure. We are developing this product in collab-
oration with Cytokinetics, Inc. (“Cytokinetics”).
38